BriaCell Therapeutics Corporation News - BCTX

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

BriaCell Announces Oral and Poster Presentations at ASCO 2024

Oral presentation by Mayo Clinic Professor and Principal Investigator, Saranya Chumsri, MDTwo poster...

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

Preclinical data shows that BriaCell’s Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune...

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice...

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

Agreement with a leading cancer treatment group to advance the clinical development of Bria-OTS+ (breast...

BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

PHILADELPHIA and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Provides Update on Alleged Illegal Trading of Public Securities

PHILADELPHIA and VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp...

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Disease control rate of 61% observed in evaluable Phase 2 patients treated with the same formulation in...

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Bria-Pros+ is based on BriaCell’s next generation personalized immunotherapy platformBria-Pros+ is capable of...

BCTX. Under $3

👍️0

QuicKtip 3 weeks ago

$BCTX Shows “Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer”

Press Release: https://bit.ly/4aJmAoc

$BCTX #CancerTreatment #Innovation

👍️0

BigHeis 1 month ago

Does anyone have information about the stock spinoff that occurred last year with this company? I have 600 shares of the spinoff security with 0 value and has remained that way since the spinoff. Thanks…

👍️0

Monksdream 1 month ago

BCTX new 52 lo

👍️0

Monksdream 1 month ago

BCTX new 52 lo

👍️0

Monksdream 2 months ago

BCTX 10Q due March 13

👍️0

Monksdream 2 months ago

BCTX new 52 week low

👍️0

Monksdream 2 months ago

BCTX new 52 week low

👍️0

QuicKtip 5 months ago

$BCTX is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. https://finance.yahoo.com/news/briacell-records-responder-remarkable-improvement-120000404.html

👍️0

Sly1969 6 months ago

Good news today. I took a entry

👍️0

Monksdream 6 months ago

BCTX new 52 week low

👍️0

benderostap4 10 months ago

2023 Anticipated Milestones, please?

👍️0

smallcapvoice 1 year ago

$BCTX $15 Price Target

Zacks Small-Cap Research just released a new report on BriaCell Therapeutics Corp. (Nasdaq: BCTX) with a $15 price target.

Read the full report here: https://scr.zacks.com/.../BCTX-Posters.../default.aspx

#Stocks #StocksToWatch #StockMarket

👍️0

smallcapvoice 1 year ago

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) was featured in an article on Seeking Alpha
Discover more about this #BioTech company here: https://bit.ly/3DoEbUc
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy
#Stocks #StocksToWatch

👍️0

Onree 1 year ago

Strange stock, but I've loved having it the past couple of years. I've mostly day traded, as there was a pretty good pattern last year, of early drops and late charges, and vice versa. I did end up getting stuck at around $10 so have been holding a lot at that level. Hopefully it runs again and I can keep chipping away at my mortgage because of the fancy researchers in Vancouver. Best of luck, all!

👍️0

chenzo11 2 years ago

Yep, I'm still here. She's getting ready to burst! Low float/high short interest, Fast track approval and now up on big volume. Gonna get interesting!

👍️0

Nickwvt 2 years ago

Under $4 by end of month

👍️0

crudeoil24 2 years ago

BriaCell Therapeutics Price Target Announced at $25.00/Share by HC Wainwright & Co.

👍️0

crudeoil24 2 years ago

BriaCell Reports Received FDA Fast Track Approval For Its Targeted Breast Cancer Immunotherapy

BCTX

👍️0

chenzo11 2 years ago

I'm still here....wait til you see what happens this week

We will dance!

👍️0

chenzo11 2 years ago

Closed above resistance of $10.50....We dance on Monday

Low float/high short interest. Setting up for big run

👍️0

lucky__stock 2 years ago

$BCTX BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/.

👍️0

lucky__stock 2 years ago

$BCTX announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board.

Dr. Ostrand-Rosenberg has more than 40 years of experience leading investigations focused on the immune system’s response to cancer. She is currently the Robert & Jane Meyerhoff Professor of Biochemistry, Emeritus, and Professor of Biological Sciences, Emeritus, University of Maryland Baltimore County, Baltimore, MD, and has been working with the University since 1977. She was also appointed as the Adjunct Professor of Pathology, Huntsman Cancer Institute (HCI), University of Utah, Salt Lake City, UT, in 2018. https://finance.yahoo.com/news/briacell-adds-pioneering-immunologist-cancer-130000276.html

👍️0

lucky__stock 2 years ago

$BCTX has added Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board!

Click here for a bio and to learn what she's bringing to the BriaCell team!

https://yhoo.it/3kbmmhX

👍️0

EyalCap 3 years ago

Easy Money for more $ZOM shares $BCTX thanks to @MrZackMorris for the tip in his Reddit community.. called this out last month on my Instagram big profits.. shorts are still all over this.. squeeze is to be prepared for.. get in profit big and get out .. October is #BreastCancerAwarenessMonth also load on $ZOM ?? it acquired Pulse Vet

$BCTX thanks to @MrZackMorris for the tip in his Reddit community.. called this out last month on my Instagram big profits.. shorts are all over this now.. squeeze is to be prepared for.. get in profit big and get out .. October is #BreastCancerAwarenessMonth also load on $ZOM 💎 pic.twitter.com/wJVS4lZydq— BL3 (@SellingStrikes) October 3, 2021

👍️0

StockHighAlert- 3 years ago

(Nasdaq: BCTX, BCTXW) (TSX-V: BCT) CEO highlights key achievements of the company including recent collaboration with ImaginAb https://yhoo.it/3CDPzc7

👍️0

StockHighAlert- 3 years ago

BriaCell Therapeutics Corp. (Nasdaq: $BCTX, $BCTXW) (TSX-V:BCT) News Alert https://yhoo.it/3gmjQ6A #stocks #medical #stockstowatch

👍️0

Nebuchadnezzar 3 years ago

BCTX

https://schrts.co/gJajQPrD

👍️0

ThurstonHowell 3 years ago

MarketsandMarkets 4th Annual Next Gen Immuno-Oncology Virtual Congress-US Edition: June 28-30, 2021
Dr. Williams will be speaking at the scientific conference at 11:30am ET on June 29, 2021.
The topic is “Personalized, off-the-shelf cellular immunotherapy for cancer”.
A copy of the presentation will be posted here: https://briacell.com/novel-technology/scientific-publications/.
For additional information on the conference and the speaker, please visit:
https://events.marketsandmarkets.com/4th-annual-next-gen-immuno-oncology-virtual-congress-us-edition/speakers

Separately, BriaCell has recently appointed Miguel A. Lopez-Lago, Ph.D. as Senior Director, Research and Development. Since 2000, Dr. Lopez-Lago has been working as a cancer scientist at Memorial Sloan-Kettering Cancer Center, New York (MSKCC). Specifically, he has investigated various aspects of tumor biology, including the development of targeted therapies for Mesothelioma and the characterization of the biological mechanisms underlying cancer metastasis. More recently, Dr. Lopez-Lago has been interested in the study of the tumor immune-microenvironment and in the development of immunotherapies for thoracic cancers using chimeric antigen receptor (CAR) T cell technologies. Since 2013, Dr. Lopez-Lago has been working as Senior Research Scientist at MSKCC. Dr. Lopez-Lago received his Bachelor of Science in Bio-Sciences and his doctorate in Molecular Biology from Santiago of Compostela University, Spain.

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer.

For additional information on BriaCell, please visit: https://briacell.com/.

👍️0

ThurstonHowell 3 years ago

https://www.globenewswire.com/en/news-release/2021/05/11/2226965/0/en/BriaCell-to-Participate-at-Upcoming-Conferences-and-Appoints-Senior-R-D-Director.html

👍️0

ThurstonHowell 3 years ago

https://www.globenewswire.com/news-release/2021/06/16/2248189/0/en/BriaCell-Therapeutics-Expands-Breast-Cancer-Platform-Technology-into-Prostate-Melanoma-and-Lung-Cancers.html

👍️0

ThurstonHowell 3 years ago

https://finance.yahoo.com/news/briacell-reports-12-0-months-111200861.html

👍️0

retireat40 3 years ago

Terrible timing though. Absolutely killed any momentum.

👍️0

HabibiFresh 3 years ago

Yeah that wasn't bad news with private offering 27m institutional investment bullish for me

Seems that market didn't panic cos of the word "offering"

However this trading really weird lol halt > drop > halt into 7 smash > > drop > halt down

👍️0

jwakstock 3 years ago

Hopefully the squeeze alone will take it over $20.

👍️0

timetomakemoney 3 years ago

Yes, Nasdaq halted it again, Those MMS who naked shorted thare stock are screwed

👍️0

cbrad10480 3 years ago

My hunch the halt is because there are a bunch of FTD shares.
Thank You!

I like your hunch, let the squeeze begin!

cbrad

👍️0

timetomakemoney 3 years ago

What the Hell, there was a market for 3 minutes then they halted it again.

👍️0

timetomakemoney 3 years ago

PPS could go either way... My hunch the halt is because there are a bunch of FTD shares.

👍️0

cbrad10480 3 years ago

I've never seen a halt for news and the news is a private placement.

Does that mean that once resumed, the pps will gravitate toward the offering price
or will it cause the pps to go up?

Sorry for the newbie question, just trying to understand a little better.

cbrad

👍️0

HabibiFresh 3 years ago

We thinking buyout with this halt? Wouldn't halt this long for dilution

👍️0

HabibiFresh 3 years ago

Yeah real curious was about to happen

👍️0

HabibiFresh 3 years ago

100% resolution for eye-bulging tumors I love it

👍️0

timetomakemoney 3 years ago

Over an hour and BCTX is still halted.

👍️0

HabibiFresh 3 years ago

Yall seen a halt before big news before?

👍️0

Penny chatter 3 years ago

Has to be more than that as it's still halted

👍️0

retireat40 3 years ago

Offering news out...$5.26 with exercise at $6.17 it appears.

👍️0

timetomakemoney 3 years ago

News Out! Public offering 5.2 million shares and warrants.

👍️0

ANTADOG 3 years ago

Company: BriaCell Therapeutics Corp.

TSX-Venture Symbol: BCT

All Issues: Yes

Reason: At the Request of the Company Pending News

Halt Time (ET): 7:45 AM

IIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC is the national self-regulatory organization which oversees all investment dealers and trading activity on debt and equity marketplaces in Canada.

SOURCE Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

BriaCell Therapeutics Corporation (BCTX)

Get an advanced news scanner tailored to your needs by ADVFN

BCTX News

BriaCell Announces Oral and Poster Presentations at ASCO 2024

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

BriaCell Provides Update on Alleged Illegal Trading of Public Securities

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Form S-3 - Registration statement under Securities Act of 1933

Form DEF 14A - Other definitive proxy statements

Form SCHEDULE 13G -

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

BCTX Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

BriaCell Therapeutics Corporation (BCTX) News

BriaCell Therapeutics Corporation (BCTX)

Get an advanced news scanner tailored to your needs by ADVFN

BCTX News

BriaCell Announces Oral and Poster Presentations at ASCO 2024

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer

BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR

BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies

BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference

BriaCell Provides Update on Alleged Illegal Trading of Public Securities

BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case

Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Form S-3 - Registration statement under Securities Act of 1933

Form DEF 14A - Other definitive proxy statements

Form SCHEDULE 13G -

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

BCTX Discussion

Your Recent History

Company

Business

Popular

Get The App